Dosing of Beta-Blocker Therapy Before, During, and After Hospitalization for Heart Failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure)
Dosing of Beta-Blocker Therapy Before, During, and After Hospitalization for Heart Failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure)
复制标题
DOI：
10.1016/j.amjcard.2008.07.045
复制
发表时间：
2008-12-01
影响因子：
2.8
通讯作者：
Young, James B.
中科院分区：
文献类型：
--
作者：
Fonarow, Gregg C.;Abraham, William T.;Young, James B.
心力衰竭(HF)指南建议对β受体阻滞剂进行滴定，以达到在主要临床试验中被证明有效的目标剂量，如果耐受的话。然而，关于心力衰竭患者在入院前、住院期间和住院后的常规临床实践中使用的β受体阻滞剂的剂量，我们知之甚少。组织的心力衰竭住院患者救命治疗计划(OPTIMIZE-HF)在全美91家学术和社区医院登记了5791名心力衰竭患者，并预先指定了60至90天的随访时间。在2373例符合出院时使用β受体阻滞剂的收缩期心衰患者中，1350例(56.9%)在入院前接受了β受体阻滞剂治疗并继续治疗，632例(26.6%)是新开始的。入院前β受体阻滞剂的平均每日总剂量为
Heart failure (HF) guidelines recommend that beta blockers be titrated to achieve the target doses shown to be effective in major clinical trials, if tolerated. Little is known, however, regarding the doses of beta blockers used in patients with HF in routine clinical practice before, during, and after hospitalization for HF. The Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) enrolled 5,791 patients admitted with HF in a registry with prespecified 60- to 90-day follow-up at 91 academic and community hospitals throughout the United States. Among 2,373 patients with systolic HF eligible for beta blockers at discharge, 1,350 (56.9%) were receiving beta-blocker therapy before admission and continued on therapy, and 632 (26.6%) were newly started. The mean total daily dose for beta blockers before hospital admission was